SCHEMBL13838501

SCHEMBL13838501

Cc1ccncc1C(=O)Nc1ccc(-c2cc(-c3nnn(C)n3)ccc2C)cn1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ WNT1 P04628 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ DYRK1A Q13627 1/20 0.43
▸ ABL1 P00519 7/20 0.43
▸ CSNK1D P48730 1/20 0.42
▸ CSNK1E P49674 1/20 0.42
▸ ABCB1 P08183 2/20 0.42
▸ ABCC1 P33527 2/20 0.42
▸ IL2 P60568 2/20 0.39
▸ TYK2 P29597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13838504 0.92 CSNK1D (0.42) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13838352 0.91 WNT1 (0.43) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13838453 0.90 IL2 (0.50) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13727744 0.89 CSNK1D (0.41) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13838348 0.84 ABL1 (0.40) ABL1CSNK1DCSNK1EABCB1ABCC1
SCHEMBL13838384 0.84 IL2 (0.43) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13838315 0.83 IL2 (0.42) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13838578 0.80 DYRK1A (0.52) WNT1GSK3BDYRK1AABL1CSNK1D
SCHEMBL13838516 0.78 ABL1 (0.49) ABL1ABCB1ABCC1IL2
SCHEMBL13838602 0.76 ABL1 (0.43) GSK3BDYRK1AABL1CSNK1DCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171446-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-06-19 — — US claimed
US-10399967-B2 Compounds for inflammation and immune-related uses PRCL Research Inc. (CA) 2019-09-03 — — US disclosed
US-10399967-B2 Compounds for inflammation and immune-related uses PRCL Research Inc. (CA) 2019-09-03 — — US disclosed
US-20170231984-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES PRCL Research Inc. (CA) 2017-08-17 — — US disclosed
US-20170231984-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES PRCL Research Inc. (CA) 2017-08-17 — — US disclosed
US-9604978-B2 Compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2017-03-28 — — US disclosed
US-9604978-B2 Compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2017-03-28 — — US disclosed
US-20140171446-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-06-19 — — US disclosed
US-20140171446-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-06-19 — — US disclosed
WO-2012151355-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2012-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171446-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR1, CCR8 WNT1 1992/4885GSK3B 1579/4885DYRK1A 4257/4885
US-10399967-B2 Compounds for inflammation and immune-related uses CXCL8, CCR1, CCR8 WNT1 1992/4885GSK3B 1579/4885DYRK1A 4257/4885
US-20170231984-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCL8, CCR1, CCR8 WNT1 1992/4885GSK3B 1579/4885DYRK1A 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback